View in EDS

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

Saved in:
Bibliographic Details
Title: Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Authors: Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Guenther K; Immatics Biotechnologies GmbH, Tuebingen, Germany., Andersson BS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mendrzyk R; Immatics Biotechnologies GmbH, Tuebingen, Germany., Alpert A; Immatics US, Inc., Houston, Texas., Wagner C; Immatics Biotechnologies GmbH, Tuebingen, Germany., Nowak A; Immatics Biotechnologies GmbH, Tuebingen, Germany., Aslan K; Immatics Biotechnologies GmbH, Tuebingen, Germany., Satelli A; Immatics US, Inc., Houston, Texas., Richter F; Immatics Biotechnologies GmbH, Tuebingen, Germany., Kuttruff-Coqui S; Immatics Biotechnologies GmbH, Tuebingen, Germany., Schoor O; Immatics Biotechnologies GmbH, Tuebingen, Germany., Fritsche J; Immatics Biotechnologies GmbH, Tuebingen, Germany., Coughlin Z; Immatics US, Inc., Houston, Texas., Mohamed AS; Immatics US, Inc., Houston, Texas., Sieger K; Immatics US, Inc., Houston, Texas., Norris B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ort R; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Beck J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vo HH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hoffgaard F; Immatics Biotechnologies GmbH, Tuebingen, Germany., Ruh M; Immatics Biotechnologies GmbH, Tuebingen, Germany., Backert L; Immatics Biotechnologies GmbH, Tuebingen, Germany., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fuhrmann D; Immatics Biotechnologies GmbH, Tuebingen, Germany., Ibrahim NK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas., Kee BK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas., Halperin DM; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas., Nogueras-Gonzalez GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vining D; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Singh H; Immatics N.V., Tuebingen, Germany., Reinhardt C; Immatics N.V., Tuebingen, Germany., Britten CM; Immatics N.V., Tuebingen, Germany., Hilf N; Immatics Biotechnologies GmbH, Tuebingen, Germany., Weinschenk T; Immatics N.V., Tuebingen, Germany., Maurer D; Immatics Biotechnologies GmbH, Tuebingen, Germany., Walter S; Immatics US, Inc., Houston, Texas.
Source: Cancer immunology research [Cancer Immunol Res] 2023 Jul 05; Vol. 11 (7), pp. 925-945.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37172100
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Guenther+K%22">Guenther K</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Andersson+BS%22">Andersson BS</searchLink>; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Mendrzyk+R%22">Mendrzyk R</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Alpert+A%22">Alpert A</searchLink>; Immatics US, Inc., Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Wagner+C%22">Wagner C</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Nowak+A%22">Nowak A</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Aslan+K%22">Aslan K</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Satelli+A%22">Satelli A</searchLink>; Immatics US, Inc., Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Richter+F%22">Richter F</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Kuttruff-Coqui+S%22">Kuttruff-Coqui S</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Schoor+O%22">Schoor O</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Fritsche+J%22">Fritsche J</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Coughlin+Z%22">Coughlin Z</searchLink>; Immatics US, Inc., Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Mohamed+AS%22">Mohamed AS</searchLink>; Immatics US, Inc., Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Sieger+K%22">Sieger K</searchLink>; Immatics US, Inc., Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Norris+B%22">Norris B</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Ort+R%22">Ort R</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Beck+J%22">Beck J</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Vo+HH%22">Vo HH</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Hoffgaard+F%22">Hoffgaard F</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Ruh+M%22">Ruh M</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Backert+L%22">Backert L</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Wistuba+II%22">Wistuba II</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Fuhrmann+D%22">Fuhrmann D</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Ibrahim+NK%22">Ibrahim NK</searchLink>; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Morris+VK%22">Morris VK</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas.<br /><searchLink fieldCode="AU" term="%22Kee+BK%22">Kee BK</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas.<br /><searchLink fieldCode="AU" term="%22Halperin+DM%22">Halperin DM</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas.<br /><searchLink fieldCode="AU" term="%22Nogueras-Gonzalez+GM%22">Nogueras-Gonzalez GM</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Kebriaei+P%22">Kebriaei P</searchLink>; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Shpall+EJ%22">Shpall EJ</searchLink>; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Vining+D%22">Vining D</searchLink>; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Hwu+P%22">Hwu P</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Singh+H%22">Singh H</searchLink>; Immatics N.V., Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Reinhardt+C%22">Reinhardt C</searchLink>; Immatics N.V., Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Britten+CM%22">Britten CM</searchLink>; Immatics N.V., Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Hilf+N%22">Hilf N</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Weinschenk+T%22">Weinschenk T</searchLink>; Immatics N.V., Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Maurer+D%22">Maurer D</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Walter+S%22">Walter S</searchLink>; Immatics US, Inc., Houston, Texas.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101614637%22">Cancer immunology research</searchLink> [Cancer Immunol Res] 2023 Jul 05; Vol. 11 (7), pp. 925-945.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101614637 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2326-6074 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223266066%22">23266066 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37172100
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/2326-6066.CIR-22-0444
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 925
    Titles:
      – TitleFull: Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tsimberidou AM
      – PersonEntity:
          Name:
            NameFull: Guenther K
      – PersonEntity:
          Name:
            NameFull: Andersson BS
      – PersonEntity:
          Name:
            NameFull: Mendrzyk R
      – PersonEntity:
          Name:
            NameFull: Alpert A
      – PersonEntity:
          Name:
            NameFull: Wagner C
      – PersonEntity:
          Name:
            NameFull: Nowak A
      – PersonEntity:
          Name:
            NameFull: Aslan K
      – PersonEntity:
          Name:
            NameFull: Satelli A
      – PersonEntity:
          Name:
            NameFull: Richter F
      – PersonEntity:
          Name:
            NameFull: Kuttruff-Coqui S
      – PersonEntity:
          Name:
            NameFull: Schoor O
      – PersonEntity:
          Name:
            NameFull: Fritsche J
      – PersonEntity:
          Name:
            NameFull: Coughlin Z
      – PersonEntity:
          Name:
            NameFull: Mohamed AS
      – PersonEntity:
          Name:
            NameFull: Sieger K
      – PersonEntity:
          Name:
            NameFull: Norris B
      – PersonEntity:
          Name:
            NameFull: Ort R
      – PersonEntity:
          Name:
            NameFull: Beck J
      – PersonEntity:
          Name:
            NameFull: Vo HH
      – PersonEntity:
          Name:
            NameFull: Hoffgaard F
      – PersonEntity:
          Name:
            NameFull: Ruh M
      – PersonEntity:
          Name:
            NameFull: Backert L
      – PersonEntity:
          Name:
            NameFull: Wistuba II
      – PersonEntity:
          Name:
            NameFull: Fuhrmann D
      – PersonEntity:
          Name:
            NameFull: Ibrahim NK
      – PersonEntity:
          Name:
            NameFull: Morris VK
      – PersonEntity:
          Name:
            NameFull: Kee BK
      – PersonEntity:
          Name:
            NameFull: Halperin DM
      – PersonEntity:
          Name:
            NameFull: Nogueras-Gonzalez GM
      – PersonEntity:
          Name:
            NameFull: Kebriaei P
      – PersonEntity:
          Name:
            NameFull: Shpall EJ
      – PersonEntity:
          Name:
            NameFull: Vining D
      – PersonEntity:
          Name:
            NameFull: Hwu P
      – PersonEntity:
          Name:
            NameFull: Singh H
      – PersonEntity:
          Name:
            NameFull: Reinhardt C
      – PersonEntity:
          Name:
            NameFull: Britten CM
      – PersonEntity:
          Name:
            NameFull: Hilf N
      – PersonEntity:
          Name:
            NameFull: Weinschenk T
      – PersonEntity:
          Name:
            NameFull: Maurer D
      – PersonEntity:
          Name:
            NameFull: Walter S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 05
              M: 07
              Text: 2023 Jul 05
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2326-6074
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Cancer immunology research
              Type: main
ResultId 1